# Maxcyte, Inc.: financial statements, quarterly

MXCT · Nasdaq · CIK 1287098 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mxct.md) · [Financials](/companies/mxct/financials.md) · [Filings](/companies/mxct/filings.md) · [Insiders](/companies/mxct/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mxct/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.2](/filings/0001558370-24-014662.md) | [4.8 d](/filings/0001558370-25-002721.md) | [5.6](/filings/0001558370-25-007005.md) | [5.0](/filings/0001558370-25-010554.md) | [5.6](/filings/0001104659-25-111396.md) | [6.1 d](/filings/0001104659-26-034557.md) | [5.7](/filings/0001104659-26-060290.md) | [5.8](/filings/0001104659-26-095971.md) | [4.6](/filings/0001104659-25-111396.md) | [4.8 d](/filings/0001104659-26-034557.md) | [4.5](/filings/0001104659-26-060290.md) | [4.9](/filings/0001104659-26-095971.md) |
| Cost of revenue | $m | [0.8](/filings/0001558370-24-014662.md) | [1.6 d](/filings/0001558370-25-002721.md) | [1.4](/filings/0001558370-25-007005.md) | [1.5](/filings/0001558370-25-010554.md) | [1.9](/filings/0001104659-25-111396.md) | [2.3 d](/filings/0001104659-26-034557.md) | [1.5](/filings/0001104659-26-060290.md) | [1.5](/filings/0001104659-26-095971.md) | [1.6](/filings/0001104659-25-111396.md) | [1.6 d](/filings/0001104659-26-034557.md) | [1.6](/filings/0001104659-26-060290.md) | [1.7](/filings/0001104659-26-095971.md) |
| Gross profit | $m | [7.2](/filings/0001558370-24-014662.md) | [14.1 d](/filings/0001558370-25-002721.md) | [9.9](/filings/0001558370-25-007005.md) | [8.9](/filings/0001558370-25-010554.md) | [6.2](/filings/0001104659-25-111396.md) | [6.4 d](/filings/0001104659-26-034557.md) | [8.9](/filings/0001104659-26-060290.md) | [7.0](/filings/0001104659-26-095971.md) | [5.2](/filings/0001104659-25-111396.md) | [5.7 d](/filings/0001104659-26-034557.md) | [8.1](/filings/0001104659-26-060290.md) | [5.6](/filings/0001104659-26-095971.md) |
| Research and development | $m | [6.3](/filings/0001558370-24-014662.md) | [5.8 d](/filings/0001558370-25-002721.md) | [6.7](/filings/0001558370-25-007005.md) | [5.6](/filings/0001558370-25-010554.md) | [5.3](/filings/0001104659-25-111396.md) | [4.6 d](/filings/0001104659-26-034557.md) | [5.9](/filings/0001104659-26-060290.md) | [6.3](/filings/0001104659-26-095971.md) | [5.3](/filings/0001104659-25-111396.md) | [3.3 d](/filings/0001104659-26-034557.md) | [3.9](/filings/0001104659-26-060290.md) | [4.3](/filings/0001104659-26-095971.md) |
| Operating income | $m | [(14.0)](/filings/0001558370-24-014662.md) | [(8.1) d](/filings/0001558370-25-002721.md) | [(12.3)](/filings/0001558370-25-007005.md) | [(12.0)](/filings/0001558370-25-010554.md) | [(14.1)](/filings/0001104659-25-111396.md) | [(12.9) d](/filings/0001104659-26-034557.md) | [(12.3)](/filings/0001104659-26-060290.md) | [(14.2)](/filings/0001104659-26-095971.md) | [(14.1)](/filings/0001104659-25-111396.md) | [(11.2) d](/filings/0001104659-26-034557.md) | [(6.2)](/filings/0001104659-26-060290.md) | [(10.2)](/filings/0001104659-26-095971.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(11.3)](/filings/0001558370-24-014662.md) | [(5.3) d](/filings/0001558370-25-002721.md) | [(9.5)](/filings/0001104659-25-111396.md) | [(9.4)](/filings/0001104659-25-111396.md) | [(11.6)](/filings/0001104659-25-111396.md) | [(10.6) d](/filings/0001104659-26-034557.md) | [(10.3)](/filings/0001104659-26-095971.md) | [(12.4)](/filings/0001104659-26-095971.md) | [(12.4)](/filings/0001104659-25-111396.md) | [(9.6) d](/filings/0001104659-26-034557.md) | [(4.8)](/filings/0001104659-26-095971.md) | [(8.9)](/filings/0001104659-26-095971.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0001558370-24-014662.md) | not reported | not reported | [(0.09)](/filings/0001558370-25-010554.md) | [(0.11)](/filings/0001104659-25-111396.md) | not reported | [(0.10)](/filings/0001104659-26-060290.md) | [(0.12)](/filings/0001104659-26-095971.md) | [(0.12)](/filings/0001104659-25-111396.md) | not reported | [(0.04)](/filings/0001104659-26-060290.md) | [(0.08)](/filings/0001104659-26-095971.md) |
| Basic EPS | $ per share | [(0.11)](/filings/0001558370-24-014662.md) | not reported | [(0.09)](/filings/0001558370-25-007005.md) | [(0.09)](/filings/0001558370-25-010554.md) | [(0.11)](/filings/0001104659-25-111396.md) | not reported | [(0.10)](/filings/0001104659-26-060290.md) | [(0.12)](/filings/0001104659-26-095971.md) | [(0.12)](/filings/0001104659-25-111396.md) | not reported | [(0.04)](/filings/0001104659-26-060290.md) | [(0.08)](/filings/0001104659-26-095971.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [49.2](/filings/0001558370-23-018314.md) | [46.5](/filings/0001558370-25-002721.md) | [22.2](/filings/0001558370-24-007085.md) | [37.5](/filings/0001558370-24-011120.md) | [37.0](/filings/0001558370-24-014662.md) | [27.9](/filings/0001104659-26-034557.md) | [23.4](/filings/0001558370-25-007005.md) | [15.2](/filings/0001558370-25-010554.md) | [13.0](/filings/0001104659-25-111396.md) | [20.1](/filings/0001104659-26-095971.md) | [14.6](/filings/0001104659-26-060290.md) | [15.0](/filings/0001104659-26-095971.md) |
| Current assets | $m | [214](/filings/0001558370-23-018314.md) | [190](/filings/0001558370-25-002721.md) | [179](/filings/0001558370-24-007085.md) | [176](/filings/0001558370-24-011120.md) | [173](/filings/0001558370-24-014662.md) | [172](/filings/0001104659-26-034557.md) | [156](/filings/0001558370-25-007005.md) | [143](/filings/0001558370-25-010554.md) | [125](/filings/0001104659-25-111396.md) | [118](/filings/0001104659-26-095971.md) | [123](/filings/0001104659-26-060290.md) | [121](/filings/0001104659-26-095971.md) |
| Total assets | $m | [267](/filings/0001558370-23-018314.md) | [268](/filings/0001558370-25-002721.md) | [258](/filings/0001558370-24-007085.md) | [251](/filings/0001558370-24-011120.md) | [249](/filings/0001558370-24-014662.md) | [239](/filings/0001104659-26-034557.md) | [230](/filings/0001558370-25-007005.md) | [220](/filings/0001558370-25-010554.md) | [213](/filings/0001104659-25-111396.md) | [203](/filings/0001104659-26-095971.md) | [194](/filings/0001104659-26-060290.md) | [185](/filings/0001104659-26-095971.md) |
| Current liabilities | $m | [16.6](/filings/0001558370-23-018314.md) | [17.9](/filings/0001558370-25-002721.md) | [13.5](/filings/0001558370-24-007085.md) | [12.3](/filings/0001558370-24-011120.md) | [17.6](/filings/0001558370-24-014662.md) | [15.8](/filings/0001104659-26-034557.md) | [12.7](/filings/0001558370-25-007005.md) | [11.6](/filings/0001558370-25-010554.md) | [16.1](/filings/0001104659-25-111396.md) | [14.3](/filings/0001104659-26-095971.md) | [10.2](/filings/0001104659-26-060290.md) | [9.9](/filings/0001104659-26-095971.md) |
| Total liabilities | $m | [33.4](/filings/0001558370-23-018314.md) | [36.1](/filings/0001558370-25-002721.md) | [31.6](/filings/0001558370-24-007085.md) | [30.2](/filings/0001558370-24-011120.md) | [35.3](/filings/0001558370-24-014662.md) | [33.2](/filings/0001104659-26-034557.md) | [30.5](/filings/0001558370-25-007005.md) | [29.0](/filings/0001558370-25-010554.md) | [33.2](/filings/0001104659-25-111396.md) | [31.0](/filings/0001104659-26-095971.md) | [26.6](/filings/0001104659-26-060290.md) | [25.9](/filings/0001104659-26-095971.md) |
| Shareholders' equity | $m | [233](/filings/0001558370-24-014662.md) | [232](/filings/0001104659-26-034557.md) | [226](/filings/0001104659-25-111396.md) | [221](/filings/0001104659-25-111396.md) | [213](/filings/0001104659-25-111396.md) | [206](/filings/0001104659-26-095971.md) | [199](/filings/0001104659-26-095971.md) | [191](/filings/0001104659-26-095971.md) | [180](/filings/0001104659-25-111396.md) | [171](/filings/0001104659-26-095971.md) | [168](/filings/0001104659-26-095971.md) | [159](/filings/0001104659-26-095971.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.2) d](/filings/0001558370-24-014662.md) | [1.0 d](/filings/0001558370-25-002721.md) | [(10.6)](/filings/0001558370-25-007005.md) | [(4.8) d](/filings/0001558370-25-010554.md) | [(4.4) d](/filings/0001104659-25-111396.md) | [(7.8) d](/filings/0001104659-26-034557.md) | [(14.4)](/filings/0001104659-26-060290.md) | [(9.9) d](/filings/0001104659-26-095971.md) | [(7.5) d](/filings/0001104659-25-111396.md) | [(2.7) d](/filings/0001104659-26-034557.md) | [(8.2)](/filings/0001104659-26-060290.md) | [(4.7) d](/filings/0001104659-26-095971.md) |
| Capital expenditure | $m | [0.7 d](/filings/0001558370-24-014662.md) | [0.9 d](/filings/0001558370-25-002721.md) | [0.8](/filings/0001558370-25-007005.md) | [0.3 d](/filings/0001558370-25-010554.md) | [0.4 d](/filings/0001104659-25-111396.md) | [0.1 d](/filings/0001104659-26-034557.md) | [0.7](/filings/0001104659-26-060290.md) | [0.6 d](/filings/0001104659-26-095971.md) | [0.3 d](/filings/0001104659-25-111396.md) | [0.2 d](/filings/0001104659-26-034557.md) | [0.1](/filings/0001104659-26-060290.md) | [0.1 d](/filings/0001104659-26-095971.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [102](/filings/0001558370-23-018314.md) | [103](/filings/0001558370-23-009167.md) | [103](/filings/0001558370-24-011120.md) | [103](/filings/0001558370-24-014662.md) | [104](/filings/0001558370-25-007005.md) | [105](/filings/0001558370-25-010554.md) | [105](/filings/0001104659-25-111396.md) | [106](/filings/0001104659-26-060290.md) | [106](/filings/0001104659-26-095971.md) | [107](/filings/0001104659-25-111396.md) | [107](/filings/0001104659-26-060290.md) | [107](/filings/0001104659-26-095971.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 103,206,206 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001104659-26-095971.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.